查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405892

前列腺癌诊断市场规模、份额、趋势分析报告：按测试类型、类型、最终用途、地区、细分市场预测，2024-2030 年

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 152 Pages | 商品交期: 2-10个工作天内

价格

前列腺癌诊断市场的成长和趋势：

Grand View Research, Inc.最新报告显示，2030年全球前列腺癌诊断市场规模预计将达到131.6亿美元，2024年至2030年复合年增长率为6.4%。

政府的支持措施、全球疾病盛行率的增加、前列腺癌盛行率的增加以及确证诊断测试的技术进步是该市场的主要驱动力。

政府采取更多有利倡议来加强以有效诊断和治疗为重点的研究，预计将在预测期内推动市场成长。例如，国家癌症研究所发起了一项题为「非裔男性前列腺癌研究：定义遗传学、肿瘤标记和社会压力的作用」（RESPOND）的研究。这项研究是调查与非裔美国男性前列腺癌相关的非生物和生物因素的最大合作研究。该计画由美国少数族裔健康研究所、NCI 和健康差异研究所与前列腺癌基金会合作发起，资金达 2,600 万美元。

诺福克大学、酵母安格利亚研究与发展中心和诺维奇大学医院开发了一种非侵入性尿液检查，有助于识别诊断后五年内需要治疗的可能性降低八倍的男性。预计此类技术进步也将在不久的将来影响市场潜力。

此外，卡罗林斯卡学院和瑞典皇家理工学院的研究人员得出结论，利用人工智慧进行空间转录组学可以帮助早期发现前列腺癌，从而改善临床诊断和治疗。空间转录组学是一种通常结合活性基因及其组织学定量分析的技术，可用于有效的疾病诊断。

前列腺癌诊断市场报告亮点

  • 到 2023 年，确认测试将占据最大的市场占有率。该细分市场的市场占有率最大，达 66.4%。确认性测试包括 PCA3 测试、超音波(TRUS) 和受影响区域的切片检查。
  • 根据最终用途，市场分为医院、门诊病人设施、居家医疗以及研究和製造。 2023年，门诊病人设施领域占据市场主导地位。透过获得医疗执照和累积经验，门诊设施彻底改变了更舒适的咨询和治疗系统。
  • 由于患病率不断上升以及政府措施不断增多，北美地区占据了最大的市场占有率。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章前列腺癌诊断市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 前列腺癌诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章前列腺癌诊断市场：测试类型的估计和趋势分析

  • 2023 年和 2030 年测试类型市场占有率
  • 细分仪表板
  • 按测试类型分類的全球前列腺癌诊断市场展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 初步测试
    • 确认检查

第五章前列腺癌诊断市场：类型估计和趋势分析

  • 类型市场占有率，2023 年和 2030 年
  • 细分仪表板
  • 按类型分類的全球前列腺癌诊断市场展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 腺癌
    • 间质细胞癌
    • 其他的

第六章前列腺癌诊断市场：最终用途估计与趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 按最终用途分類的全球前列腺癌诊断市场展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 医院
    • 门诊设施
    • 居家护理
    • 研究/製造

第七章前列腺癌诊断市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • MDx Health
    • Myriad Genetics, Inc.
    • Abbott Laboratories
    • F. Hoffman-La Roche AG
    • Bayer AG
    • Siemens Healthcare GmbH
    • OPKO Health, Inc.
    • Genomic Health.
    • Pfizer Inc.
Product Code: GVR-2-68038-548-9

Prostate Cancer Diagnostics Market Growth & Trends:

The global prostate cancer diagnostics market size is expected to reach USD 13.16 billion by 2030, expanding at a CAGR of 6.4% from 2024 to 2030,according to a new report by Grand View Research, Inc. Supportive government initiatives, increasing disease prevalence across the globe, and a rise in the prevalence of prostate cancer coupled with technological advancements in confirmatory diagnostic tests are the major drivers for this market.

A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled 'Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress' (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.

Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.

Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.

Prostate Cancer Diagnostics Market Report Highlights:

  • Confirmatory tests held the largest market share in 2023. The segment holds largest market share by 66.4%. Confirmatory tests include the PCA3 test, Transrectal Ultrasound (TRUS), and biopsy of the affected portion
  • Based on end use, the market is segmented into hospitals, outpatient facilities, home care, and research & manufacturing. In 2023, the Outpatient Facilities segment dominated the market. Outpatient Facilities have revolutionized and developed more comfortable consulting and treatment systems with the acquisition and experience of the licensed physician
  • The North American region holds the largest market share owing to rising prevalence and the rise in government initiatives to enhance diagnosis

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type
    • 2.2.2. Type
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of prostate cancer
      • 3.2.1.2. Increasing global geriatric population
      • 3.2.1.3. Technological advancements in the field of cancer diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of diagnostics
  • 3.3. Prostate Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Preliminary Tests
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. PSA Tests
      • 4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Free PSA Test
      • 4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Total PSA Test
      • 4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Other Preliminary Tests
      • 4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Confirmatory Tests
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Pca3 Test
      • 4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Trans-Rectal Ultrasound
      • 4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Biopsy Test
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Prostate Cancer Diagnostics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Adenocarcinoma
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Interstitial Cell Carcinoma
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Other
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Outpatient Facilities
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Home Care
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Research & Manufacturing
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. MDx Health
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Test Type benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Myriad Genetics, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Test Type benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Abbott Laboratories
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Test Type benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffman-La Roche AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Test Type benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Bayer AG
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Test Type benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Siemens Healthcare GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Test Type benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. OPKO Health, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Test Type benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Genomic Health.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Test Type benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Pfizer Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Test Type benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Canada Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 14 Europe Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Germany Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 20 UK Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 France Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Italy Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Spain Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Norway Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 China Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Japan Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 India Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 South Korea Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 57 Australia Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 Thailand Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 77 MEA Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 86 UAE Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Prostate Cancer Diagnostics market: market outlook
  • Fig. 14 Prostate Cancer Diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Prostate Cancer Diagnostics market driver impact
  • Fig. 20 Prostate Cancer Diagnostics market restraint impact
  • Fig. 21 Prostate Cancer Diagnostics market strategic initiatives analysis
  • Fig. 22 Prostate Cancer Diagnostics market: Test Type movement analysis
  • Fig. 23 Prostate Cancer Diagnostics market: Test Type outlook and key takeaways
  • Fig. 24 Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 25 PSA Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 26 Free PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Total PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 28 Other Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 29 Confirmatory Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 30 Pca3 Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 31 Trans-Rectal Ultrasound Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 32 Biopsy Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 33 Prostate Cancer Diagnostics Market: Type movement Analysis
  • Fig. 34 Prostate Cancer Diagnostics market: Type outlook and key takeaways
  • Fig. 35 Adenocarcinoma market estimates and forecasts, 2018 - 2030
  • Fig. 36 Interstitial Cell Carcinoma market estimates and forecasts,2018 - 2030
  • Fig. 37 Other market estimates and forecasts,2018 - 2030
  • Fig. 38 Prostate Cancer Diagnostics market: End Use movement analysis
  • Fig. 39 Prostate Cancer Diagnostics market: End Use outlook and key takeaways
  • Fig. 40 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 41 Outpatient Facilities market estimates and forecasts,2018 - 2030
  • Fig. 42 Home Care market estimates and forecasts, 2018 - 2030
  • Fig. 43 Research & Manufacturing market estimates and forecasts,2018 - 2030
  • Fig. 44 Global Prostate Cancer Diagnostics market: Regional movement analysis
  • Fig. 45 Global Prostate Cancer Diagnostics market: Regional outlook and key takeaways
  • Fig. 46 Global Prostate Cancer Diagnostics market share and leading players
  • Fig. 47 North America market share and leading players
  • Fig. 48 Europe market share and leading players
  • Fig. 49 Asia Pacific market share and leading players
  • Fig. 50 Latin America market share and leading players
  • Fig. 51 Middle East & Africa market share and leading players
  • Fig. 52 North America: SWOT
  • Fig. 53 Europe SWOT
  • Fig. 54 Asia Pacific SWOT
  • Fig. 55 Latin America SWOT
  • Fig. 56 MEA SWOT
  • Fig. 57 North America, by country
  • Fig. 58 North America
  • Fig. 59 North America market estimates and forecasts, 2018 - 2030
  • Fig. 60 U.S.
  • Fig. 61 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 62 Canada
  • Fig. 63 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 64 Europe
  • Fig. 65 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 66 UK
  • Fig. 67 UK market estimates and forecasts, 2018 - 2030
  • Fig. 68 Germany
  • Fig. 69 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 70 France
  • Fig. 71 France market estimates and forecasts, 2018 - 2030
  • Fig. 72 Italy
  • Fig. 73 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 74 Spain
  • Fig. 75 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 76 Denmark
  • Fig. 77 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 78 Sweden
  • Fig. 79 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 80 Norway
  • Fig. 81 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 82 Asia Pacific
  • Fig. 83 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 84 China
  • Fig. 85 China market estimates and forecasts, 2018 - 2030
  • Fig. 86 Japan
  • Fig. 87 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 88 India
  • Fig. 89 India market estimates and forecasts, 2018 - 2030
  • Fig. 90 Thailand
  • Fig. 91 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Korea
  • Fig. 93 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 94 Australia
  • Fig. 95 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 96 Latin America
  • Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 98 Brazil
  • Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 100 Mexico
  • Fig. 101 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 102 Argentina
  • Fig. 103 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 104 Middle East and Africa
  • Fig. 105 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 106 South Africa
  • Fig. 107 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 108 Saudi Arabia
  • Fig. 109 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 110 UAE
  • Fig. 111 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 112 Kuwait
  • Fig. 113 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 114 Market share of key market players - Prostate Cancer Diagnostics market